文献速递免疫规划卫生政策与健康促进

会议摘要:2023年全球疫苗与免疫研究论坛

Meeting summary: Global vaccine and immunization research forum, 2023.
PubMed 文献 · Vaccine · 2025-01-05

2023年全球疫苗与免疫研究论坛在韩国召开,各国研究者讨论了疫苗与免疫进展。与会者将新冠经验用于未来突发应对,推进原型疫苗早期开发并建设区域疫苗研发与生产能力,近期多个疫苗获批,疟疾疫苗实施扩大且第二种疟疾疫苗获世界卫生组织推荐,艾滋病疫苗唯一剩余3期试验已终止。

要点

  • 利益相关方借鉴新冠经验推进原型疫苗早期开发,并建设区域疫苗研发与生产能力以加速未来应急公平可及。
  • 近期获批疫苗包括针对老年人的呼吸道合胞病毒疫苗和通过母体免疫保护婴儿的呼吸道合胞病毒疫苗、一种新登革热疫苗及既往紧急使用授权的Covid-19疫苗。
  • 疟疾疫苗实施正在扩大,第二种疟疾疫苗已获世界卫生组织推荐;艾滋病疫苗开发受挫,唯一剩余的3期试验已终止。

核心结论

  • 合作是2023年全球疫苗与免疫研究论坛的统一主题,迄今进展由多方贡献者共同努力实现,未来确保所有人公平获得疫苗仍将离不开合作。

研究设计与样本

  • 2023年全球疫苗与免疫研究论坛在韩国召开,来自世界各地的研究者参会讨论疫苗与免疫的进展和机会。

主要发现

  • 许多利益相关方正在将Covid-19的经验应用于未来紧急情况,推进原型疫苗的早期开发以加速对下一次新发传染病的应对,并建设区域疫苗研究、开发和制造能力以加速下一次紧急情况中疫苗的公平可及。
  • 近期疫苗获批包括:针对老年人的呼吸道合胞病毒疫苗和通过母体免疫保护婴儿的呼吸道合胞病毒疫苗;一种新的登革热病毒疫苗;以及此前根据紧急使用授权上市的Covid-19疫苗的获批。
  • 疟疾疫苗实施正在扩大,第二种疟疾疫苗已获世界卫生组织推荐;在人类免疫缺陷病毒疫苗开发方面遭遇挫折,唯一剩余的3期试验已终止。
  • 在免疫方面,实现可及性和公平性的挑战正变得更清晰,应对这些挑战的策略也在涌现;对疫苗 uptake 的行为和社会决定因素的更好理解以及用于测量和改变疫苗接种驱动因素的经过验证的工具包正在为项目设计和服务提供提供信息,有助于改善 uptake。
  • 实施研究对HPV和疟疾疫苗交付至关重要,将对交付新的呼吸道合胞病毒疫苗和许多其他正在开发的疫苗至关重要;疫苗日益多样化和免疫规划复杂性增加导致对简化方案、联合疫苗和其他促进交付的创新更大兴趣。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

At the 2023 Global Vaccine and Immunization Research Forum (GVIRF), researchers from around the world gathered in the Republic of Korea to discuss advances and opportunities in vaccines and immunization. Many stakeholders are applying the lessons of Covid-19 to future emergencies, by advancing early-stage development of prototype vaccines to accelerate response to the next emerging infectious disease, and by building regional vaccine research, development, and manufacturing capacity to speed equitable access to vaccines in the next emergency. Recent vaccine licensures include: respiratory syncytial virus vaccines, both for the elderly and to protect infants through maternal immunization; a new dengue virus vaccine; and licensure of Covid-19 vaccines previously marketed under emergency use authorizations. Malaria vaccine implementation is expanding and a second malaria vaccine has been recommended by the World Health Organization. In a setback for human immunodeficiency virus vaccine development, the only remaining Phase 3 trial has been discontinued. In immunization, greater clarity is emerging on the challenges of achieving access and equity, along with strategies to address those challenges. A better understanding of behavioral and social determinants of vaccine uptake and a validated toolkit for measuring and modifying the drivers of vaccination is informing program design and service delivery, contributing to improved uptake. Implementation research, which has been essential for human papillomavirus and malaria vaccine delivery, will be critical for delivering the new respiratory syncytial virus vaccines and for many other vaccines currently in development. The growing diversity of vaccines and complexity of immunization programs are leading to greater interest in simplified regimens, combination vaccines, and other innovations to facilitate delivery. Collaboration emerged as the unifying theme of GVIRF 2023, underscoring that the combined efforts of many contributors have enabled progress thus far, and going forward will continue to be essential to ensure equitable access to vaccines for all.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Giersing B, Mo AX, Hwang A, et al. Meeting summary: Global vaccine and immunization research forum, 2023. Vaccine. 2025. PMID: 39752894. doi:10.1016/j.vaccine.2024.126686

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。